Selected article for: "disease onset and immune response"
Author: Simioli, Francesca; Martino, Maria; Annunziata, Anna; Carannante, Novella; Fiorentino, Giuseppe
Title: Therapeutic approach for severe COVID-19 and immunocompromised patients. A case series
  • Cord-id: wvntmyin
  • Document date: 2021_3_24
    • ID: wvntmyin
    Snippet: BACKGROUND: COVID-19 is a potentially critical infectious disease. Inflammatory response and disease severity may vary according to immune system status. The aim of this case series is to investigate different presentation of COVID-19 in immunocompromised patients. METHODS: this is a single centre case series about 17 immunocompromised patients admitted to our respiratory department during the recent COVID-19 pandemic. White blood cell count, C reactive protein, interleukin 6, lymphocytic subpop
    Document: BACKGROUND: COVID-19 is a potentially critical infectious disease. Inflammatory response and disease severity may vary according to immune system status. The aim of this case series is to investigate different presentation of COVID-19 in immunocompromised patients. METHODS: this is a single centre case series about 17 immunocompromised patients admitted to our respiratory department during the recent COVID-19 pandemic. White blood cell count, C reactive protein, interleukin 6, lymphocytic subpopulation count (CD4(+), CD8(+), CD20(+)) and immunoglobulin count (IgG, IgM, IgA) were measured at hospitalization. RESULTS: the most common causes of immunosuppression observed in our severe COVID-19 population are hematological malignancies, immunosuppressant drugs for transplant, primary immunodeficiency and inflammatory bowel disease. Onset symptoms were fever (88%), cough (53%), dyspnoea (24%), asthenia (35%), anosmia and/or ageusia (17%), expectoration (12%). Compared to benign conditions, patients with malignancies show a lower lymphocytic count (490 vs 1100 cells/uL) and higher interleukin 6 (33 vs 13 pg/mL). CONCLUSIONS: immunocompromised patients are at risk of adverse outcome from COVID-19. Hematological malignancies and anti-CD20 therapies induce a high risk. Primary immunodeficiency and classical immunosuppressant such as calcineurin inhibitors and antimetabolites share an intermediate risk.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low survival rate: 1
    • acute ards respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphocytic leukemia: 1
    • administered therapy and lmwh weight heparin: 1
    • administered therapy and low molecular lmwh weight heparin: 1
    • administered therapy and lung involvement: 1
    • administered therapy and lymphocyte count: 1
    • lmwh weight heparin and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh weight heparin and low molecular lmwh weight heparin prophylactic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • lmwh weight heparin and lymphocyte count: 1
    • low molecular lmwh weight heparin and lymphocyte count: 1
    • lung involvement and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25